Brief: Brickell Biotech Reports Q3 Revenue Of $100,000

Fresh Tracks Therapeutics

12/11/2020 21:08

Nov 12 (Reuters) - Brickell Biotech Inc  BBI.O :
    * BRICKELL BIOTECH REPORTS THIRD QUARTER 2020 FINANCIAL
RESULTS
AND PROVIDES CORPORATE UPDATE
    * Q3 REVENUE $100,000 VERSUS $1.2 MILLION
    * PLANNED COMMERCIAL LAUNCH OF ECCLOCK IN JAPAN BY
DEVELOPMENT
PARTNER, KAKEN, EXPECTED BY END OF 2020
    * BRICKELL BIOTECH - RECENTLY COMPLETED CAPITAL RAISE
EXPECTED TO
FULLY FUND U.S. PIVOTAL PHASE 3 PROGRAM, WITH TOPLINE RESULTS
ANTICIPATED IN Q4 2021
    * BRICKELL BIOTECH - ON TRACK TO INITIATE CARDIGAN II STUDY,
SECOND U.S. PIVOTAL PHASE 3 CLINICAL STUDY, LATER THIS YEAR
    * BRICKELL BIOTECH - QTRLY NET LOSS PER COMMON SHARE
ATTRIBUTABLE
TO COMMON STOCKHOLDERS$0.15

Source text for Eikon:  ID:nGNX2LvNsk 
Further company coverage:  BBI.O 

 ((Reuters.Briefs@thomsonreuters.com;))